Skip to main content
Log in

Cyclosporine absorption profiles in pediatric kidney and liver transplant patients

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Cyclosporine absorption profiling uses either the area under the concentration curve in the first 4 h post dose, AUC(0–4), or the concentration 2 h post dose (C2) to optimize immunosuppression in adult kidney and liver transplantation. We characterized C2 versus AUC(0–4) relationships over time after transplant and across transplant indications in 56 pediatric transplant patients. There were 36 kidney transplant patients aged 9.7±3.9 years. Nineteen of these patients were studied in the de novo period on day 7 post transplant and 17 in the maintenance phase more than 1 year post transplant. In addition, 20 liver transplant patients aged 8.9±4.2 years were studied in the maintenance phase. All patients had five blood samples collected over the 12-h dose interval that were analyzed by validated assay methods at a central laboratory. Pediatric C2 values were 1,463±658 ng/ml for de novo kidney, 954±322 ng/ml for maintenance kidney, and 619±339 ng/ml for maintenance liver transplant patients. C2 was a strong predictor of AUC(0–4) in all three pediatric groups, with coefficients of determination (r 2) ranging from 0.861 to 0.936. Although data were limited from the de novo period, the C2 versus AUC(0–4) regression was consistent over time after transplant and between transplant indications, with a regression slope of 2.50 in de novo kidney, 2.54 in maintenance kidney, and 2.76 in maintenance liver transplant recipients. These slopes were also comparable to that in adult maintenance kidney transplant patients (2.60). In conclusion, C2 versus AUC(0–4) relationships demonstrated consistency over time (de novo vs. maintenance phase), between transplant indications (kidney vs. liver), and across age groups (pediatric vs. adult patients). Average C2 values achieved with current pediatric cyclosporine dosing practices cluster around the target C2 ranges recommended for adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dunn S (2000) Neoral use in the pediatric transplant recipient. Transplant Proc 32 [Suppl 3A]:20S–26S

  2. Cooney GF, Habucky K, Hoppu K (1997) Cyclosporine pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 32:481–495

    Google Scholar 

  3. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A (2003) Longitudinal evaluation of the pharmacokinetics of cyclosporine microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 levels as a marker for absorption. Pediatr Transplant 7:282–288

    Google Scholar 

  4. Dunn S, Cooney G, Sommeraurer J, Lindsay C, McDiarmid S, Wong RL (1997) Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation 63:1762–1767

    CAS  PubMed  Google Scholar 

  5. Nashan B, Cole E, Levy G, Thervet E (2002) Clinical validation studies of Neoral C2 monitoring: a review. Transplantation 73:S3–S11

    Google Scholar 

  6. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, Mies S, Pollard SG, Varo E, Villani F, Johnston A (2002) Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 73:953–959

    CAS  PubMed  Google Scholar 

  7. Toselli L, Pfeffer P, Stefoni S, Thervet E, Fornairon S, Keown P (2002) Minimal rejection and excellent graft function by Neoral C2 monitoring in renal transplantation: Interim results of MO2ART, a randomized prospective international study. Transplantation 74 [Suppl]:476–477

    Google Scholar 

  8. Levy G, Smith R, O’Grady C, Lilly LB, Girgrah N, Greig PD, Grant D (2002) Long term follow up of maintenance liver transplant patients converted to C2 cyclosporine using Neoral immunosuppression (abstract). Am J Transplant 2 [Suppl 3]:370

  9. Cole E, Maham N, O’Grady C, Hammill J, Cardella C (2003) C2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. Transplantation (in press)

  10. Levy G, Thervet E, Lake J, Uchida K (2002) Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 73:S12–S18

    Google Scholar 

  11. Cole E, Midtvedt K, Johnston A, Pattison J, O’Grady C (2002) Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation 73:S19–S22

    Google Scholar 

  12. Hoyer PF, Vester U (2001) Refining immunosuppressive protocols in pediatric renal transplant recipients. Transplant Proc 33:3587–3589

    Article  CAS  PubMed  Google Scholar 

  13. Dunn S, Falkenstein K, Cooney G (2001) Neoral C2 monitoring in pediatric liver transplant recipients. Transplant Proc 33:3094–3095

    Article  CAS  PubMed  Google Scholar 

  14. Hoyer PF, Ettenger R, Kovarik JM, Webb NAJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H (2003) Everolimus in pediatric de novo renal transplant patients. Transplantation 75:2082–2085

    Google Scholar 

  15. VanDamme-Lombaerts R, Webb NAY,Hoyer PF,Mahan J,Lemire J,Ettenger R,McMahon L,Cambon N,Boger R, Kovarik JM (2002) Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 6:147–152

    Article  CAS  PubMed  Google Scholar 

  16. Punch J, Dunn S, Lobritto S, Moeller VM, Riviere GJ, Kovarik JM (2002) Pharmacokinetics and tolerability of everolimus in stable pediatric liver transplant patients (abstract). Am J Transplant 2 [Suppl 3]:296

  17. Brignol N, McMahon LM, Luo S, Tse FLS (2000) High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood. Rapid Commun Mass Spectrom 14:1965–1971

    Article  CAS  PubMed  Google Scholar 

  18. Kovarik JM, Kaplan B, Vitko S, McMahon L, Attinger M, Boger R, Rordorf C (2001) Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials (abstract). Am J Transplant 1 [Suppl 1]:475

Download references

Acknowledgements

We thank Louis McMahon and Marisel Rouilly for analyzing the cyclosporine blood samples in these studies. R.E. was supported in part by the Casey Lee Bell Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. M. Kovarik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovarik, J.M., Hoyer, P.F., Ettenger, R. et al. Cyclosporine absorption profiles in pediatric kidney and liver transplant patients. Pediatr Nephrol 18, 1275–1279 (2003). https://doi.org/10.1007/s00467-003-1260-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-003-1260-8

Keywords

Navigation